OXON Epidemiology
This sponsor has funded 3 studies across 3 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 23245 | Ongoing | Not included in RMP | Systematic Review and meta-analysis of PASS Studies Assessing the Effectiveness of Risk Minimisation Measures | No | No |
| 35147 | Ongoing | Not included in RMP | Real-time systematic review and meta-analysis of non-randomised comparative treatment studies for COVID-19 | No | No |
| 35254 | Ongoing | Not included in RMP | A retrospective study to evaluate the clinical effectiveness and safety of treatments for Covid-19 hospitalised patients and to determine prognostic... | No | No |
PAS by Risk Management Plan (RMP) requirement
OXON Epidemiology
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
OXON Epidemiology
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
OXON Epidemiology
3 Study countries specified are the following:
- Germany
- Spain
- United Kingdom